Latest Profitability News

Monadelphous Group Limited reported a robust 12% revenue increase to $2.27 billion and a 35% rise in net profit, driven by strong demand across resources and energy sectors and a record $2.5 billion in new contracts.

Challenger Limited reported a solid 9% rise in normalised NPAT to $456 million for FY25, alongside an 11% dividend increase to 29.5 cents per share, underscoring its strategic momentum and capital strength. The company’s outlook for FY26 remains positive, with guidance pointing to continued growth and shareholder returns amid evolving retirement income reforms.

Monadelphous Group Limited reported a robust FY25 with $2.27 billion revenue and $158 million net profit, underpinned by strong contract wins and growth in energy and resources sectors.

Challenger Limited reported a robust FY25 with a 9% rise in normalised profit and a strategic push into digital transformation and retirement income solutions.

Challenger Limited celebrates four decades with a robust 9% rise in net profit and a strategic digital transformation, positioning itself at the forefront of Australia’s retirement income market.

Monadelphous Group Limited has announced a fully franked ordinary dividend of AUD 0.39 per share for the half-year ending June 2025, alongside a Dividend Reinvestment Plan offering shareholders a flexible way to reinvest.

Monadelphous Group Limited has reported a robust 35% increase in net profit for the 2025 financial year, alongside a 7% revenue rise, prompting a notable dividend hike.

Challenger Limited reported a robust 48% increase in net profit after tax for FY2025, alongside a 4.6% rise in revenue and an 11.3% dividend hike, reflecting improved operational performance and financial resilience.

HUB24 Limited reported robust FY25 results with revenue climbing 24% to $406.6 million and underlying net profit after tax soaring 44%. The company’s platform funds under administration grew 34%, underpinning a 47% increase in fully franked dividends.

CSL Limited reported solid FY25 financials with 5% revenue growth and announced a strategic transformation including a $500 million annual cost saving target and plans to spin off its vaccine business, CSL Seqirus, as a separate ASX-listed entity.

CSL Limited reported robust FY25 results alongside a sweeping strategic overhaul, including a major cost-saving program and plans to spin off its vaccine unit CSL Seqirus as a standalone ASX-listed company.

CSL Limited posted a 14% rise in net profit for FY2025, underpinned by strong immunoglobulin sales and new product launches, while announcing plans to demerge its vaccines business, CSL Seqirus, to sharpen strategic focus.